Close
Smartlab Europe
Inizio Ignite

Clinical Trials

AstraZeneca and Daiichi Report Datroway Efficacy for TNBC

Datroway, a cancer drug developed by AstraZeneca and Daiichi Sankyo, has demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in the TROPION-Breast02 Phase III trial. The...

Novartis-Argo $5.2 Licensing Deal for Heart Drugs

Argo Biopharmaceutical from China, which happens to be a clinical-stage biotechnology company that’s focused on developing next-generation siRNA therapeutics, has gone on to enter into an additional strategic partnership along with Novartis pertaining to numerous cardiovascular assets that prevail...

Pharma Supply Chain and Customs Clearance Solutions

The Critical Challenge of Pharmaceutical Customs Clearance The pharmaceutical industry faces unprecedented challenges in global supply chain management, particularly when navigating the complex landscape of international customs clearance for clinical trial materials and commercial drug batches. Customs delays can have...

FDA Aims to Decrease Animal Testing as Tech Gathers Pace

Drug developers are raising the adoption of AI technologies when it comes to discovery and safety testing in order to get rapid as well as cheaper results, which, by the way, happen to be in line with an FDA...

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to stand on the edge of fundamental transformation as the real-world evidence clinical development methods go on to reshape how one gauges the therapeutic intervention. This kind of revolution happens to...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology data represents the most significant advancement in precision medicine since the completion of the Human Genome Project. This multi-omic data integration precision medicine approach promises to revolutionize healthcare by providing...

PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder cancer Results will be discussed with global health authorities for...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »